~~<i id='EC7DBE50F8'><strike id='EC7DBE50F8'><tt id='EC7DBE50F8'><pre id='EC7DBE50F8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：entertainment 2025-10-04 04:01:50 - browse：1

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Statins may not be needed by millions of people, study suggests

Wikipedia

explore

focus

hotspot

AdobeIt’snosecretthataluckyfewseemtoglideintooldage,theyearssettlinggracefullyontheirbodies,whileoth

WSS

Pharma companies must ensure equitable access to obesity drugs

Use wet bulb globe temperature, not heat index, to protect workers

Medical device trials still don't enroll enough women, study finds

My daughter's legacy lives on through her writing, phage therapy

Sanofi strikes deal with Novavax, boosting the vaccine maker

Brain worms: The science behind RFK Jr.'s parasitic infection

hotspot

fashion

Wikipedia

At least 13 dead in Texas as scorching temps continue

Sanofi strikes deal with Novavax, boosting the vaccine maker

As demand for Covid shots wanes, Moderna seeks its next success

Telehealth startups turn to complex chronic diseases

What does generative AI mean for health care? We asked experts

Sanofi strikes deal with Novavax, boosting the vaccine maker

Medicare proposal to cover medical devices draws a mixed reaction

Lilly's Alzheimer's drug donanemab backed by FDA advisers

As demand for Covid shots wanes, Moderna seeks its next success

After gene therapy, two congenitally deaf children hear for the first time

explore

5 takeaways from STAT's examination of Zynex Medical

Sanofi strikes deal with Novavax, boosting the vaccine maker

First recipient of genetically engineered pig kidney has died

Steward Health Care files for bankruptcy

Sanofi strikes deal with Novavax, boosting the vaccine maker

What nurses really want: sufficient staffing for patient care

focus

focus

hotspot

hotspot